Postmenopausal Vaginal Atrophy Drugs

Postmenopausal Vaginal Atrophy Drugs Market Outlook

The global postmenopausal vaginal atrophy drugs market is anticipated to reach USD 2.1 billion by 2035, with a compound annual growth rate (CAGR) of approximately 6.5% during the forecast period of 2025-2035. This growth is largely driven by the increasing awareness of postmenopausal conditions among women and their healthcare providers, coupled with the rising prevalence of postmenopausal symptoms such as vaginal dryness, itching, and discomfort. As the population of postmenopausal women continues to grow globally, there is a significant uptick in demand for effective treatment options. Furthermore, advancements in drug formulations and delivery methods are expected to enhance patient compliance, thereby boosting market growth. The availability of a wide range of therapeutic options catering to individual needs is anticipated to foster a more favorable market environment.

Growth Factor of the Market

One of the primary growth factors propelling the postmenopausal vaginal atrophy drugs market is the aging population, especially the increasing number of women aged 50 and above. As women live longer due to advancements in healthcare, they are more likely to experience the symptoms associated with menopause, including vaginal atrophy. Moreover, increased awareness and education about postmenopausal health issues among women and healthcare professionals have led to more proactive approaches to seeking treatment. The acceptance of hormonal and non-hormonal therapies as effective treatment solutions for vaginal atrophy also plays a significant role in market expansion. Additionally, the rise of telemedicine and online pharmacies has made it easier for women to access these treatments discreetly, further driving market growth. Lastly, ongoing research and development in innovative drug delivery systems, such as localized therapies, are anticipated to enhance treatment efficacy and patient satisfaction.

Key Highlights of the Market

• The market is estimated to grow at a CAGR of 6.5% from 2025 to 2035.
• Estrogen creams and vaginal moisturizers are among the most widely used product types.
• Online pharmacies are witnessing significant growth due to increased digitalization and access.
• Northern America holds the largest market share, driven by advanced healthcare systems.
• Awareness campaigns are helping to destigmatize discussions about menopausal health issues.

By Product Type

Estrogen Creams:

Estrogen creams are a popular treatment option for postmenopausal vaginal atrophy due to their direct application to the vaginal area, providing localized relief. These creams work by replenishing estrogen levels, which helps restore the natural moisture and elasticity of vaginal tissues. The effectiveness of estrogen creams in alleviating the symptoms of vaginal atrophy has been supported by numerous clinical studies, increasing their acceptance among healthcare providers. As the primary hormonal treatment for this condition, estrogen creams have captured a significant market share and are expected to continue to do so, particularly as more women seek effective and immediate relief from their symptoms. Furthermore, the convenience of use and the ability to tailor dosages to individual needs contribute to their popularity.

Vaginal Moisturizers:

Vaginal moisturizers are an essential component of the postmenopausal vaginal atrophy drugs market, particularly for women looking for non-hormonal treatment options. These products provide long-lasting moisture and relief from dryness without the use of hormonal ingredients. Vaginal moisturizers are typically formulated with substances such as hyaluronic acid and other emollients, which help maintain vaginal moisture levels. Their widespread availability over-the-counter makes them accessible to a larger audience, further driving their market presence. Additionally, the increasing preference for natural and safe products among postmenopausal women has propelled the demand for vaginal moisturizers, as they are perceived as less invasive and safer alternatives to hormonal therapies.

Vaginal Lubricants:

Vaginal lubricants play a crucial role in enhancing sexual comfort and reducing friction during intercourse, which can be particularly problematic for women experiencing vaginal atrophy. These products are designed to alleviate discomfort and improve overall sexual experience, making them an important segment of the market. The variety of available formulations, including water-based, silicone-based, and oil-based lubricants, allows women to choose products that suit their individual preferences and needs. As discussions surrounding sexual health become more open and accepting, the demand for vaginal lubricants has increased significantly. This growth trend is expected to continue as more women seek solutions to enhance their quality of life post-menopause.

Hormone Replacement Therapy:

Hormone replacement therapy (HRT) encompasses a range of treatments designed to relieve menopausal symptoms, including vaginal atrophy. This therapy often involves the administration of estrogen, either alone or in combination with progestin, to restore hormonal balance. HRT is recognized for its efficacy in alleviating not only vaginal irritation but also other systemic symptoms of menopause. Although HRT has generated considerable debate regarding its safety and potential risks, recent advancements in personalized medicine have paved the way for safer and more effective HRT options. The increasing acceptance of HRT among healthcare providers and patients alike has led to its growing adoption in the treatment of postmenopausal vaginal atrophy.

Non-Hormonal Therapies:

Non-hormonal therapies are gaining traction in the postmenopausal vaginal atrophy drugs market, particularly among women who prefer alternatives to hormonal treatments. These therapies include products containing natural ingredients, such as herbal supplements and vaginal gels with hyaluronic acid, that aim to alleviate dryness and discomfort without the risks associated with hormone therapy. The appeal of non-hormonal options is particularly strong among women who are concerned about the potential side effects of hormone replacement therapy. As more women seek holistic and natural solutions for their healthcare needs, the market for non-hormonal therapies is expected to expand significantly, catering to a growing demographic interested in maintaining vaginal health without hormone intervention.

By Application

Hospital Pharmacies:

Hospital pharmacies play an integral role in the postmenopausal vaginal atrophy drugs market, particularly for patients requiring prescription medications or specialized therapies. These pharmacies are equipped to provide individualized care and consultations, ensuring that patients receive the most appropriate medications based on their specific health conditions and needs. The presence of healthcare professionals, such as pharmacists, allows for comprehensive patient education regarding the use of vaginal atrophy treatments, further enhancing patient adherence. As hospitals continue to emphasize women's health services, the significance of hospital pharmacies in managing postmenopausal conditions is likely to grow, contributing to market expansion.

Retail Pharmacies:

Retail pharmacies serve as a crucial point of access for women seeking over-the-counter solutions for postmenopausal vaginal atrophy. With a wide array of products available, including vaginal moisturizers, lubricants, and hormone therapies, retail pharmacies provide women with convenient options for managing their symptoms. The visibility and accessibility of these products in retail settings increase awareness and encourage women to seek treatment for their conditions. Retail pharmacies often offer promotions and educational resources to help women make informed decisions about their health, which further drives the growth of this segment in the market.

Online Pharmacies:

The rise of online pharmacies has transformed the way women access treatments for postmenopausal vaginal atrophy, providing a discreet and convenient method to purchase medications and wellness products. As more women become comfortable with online shopping, the demand for online pharmacies has surged, leading to significant growth in this segment. These platforms often offer a wider selection of products compared to brick-and-mortar stores and frequently provide detailed product information and reviews, assisting consumers in their decision-making process. Furthermore, the ongoing trend of telehealth services has enabled healthcare providers to prescribe medications digitally, allowing for seamless access to necessary treatments. This evolution in the retail landscape is likely to continue shaping the postmenopausal vaginal atrophy drugs market in the coming years.

Drug Stores:

Drug stores, similar to retail pharmacies, play a vital role in the distribution of postmenopausal vaginal atrophy drugs. They stock a range of products that cater to the specific needs of women, including both hormonal and non-hormonal treatments. The convenience of drug stores makes them an attractive option for women seeking solutions for vaginal health concerns without the need for a prescription. With a focus on customer service and providing personalized recommendations, drug stores can enhance the shopping experience for women, encouraging them to explore treatment options tailored to their needs. As awareness of menopausal health issues continues to grow, drug stores are expected to see an increase in foot traffic and product sales.

By Distribution Channel

Prescription-based:

The prescription-based distribution channel is crucial for delivering more specialized treatments for postmenopausal vaginal atrophy. Medications that require a prescription are typically more potent and tailored to the patient’s specific needs, allowing healthcare providers to monitor their efficacy and side effects closely. Prescription medications are often recommended for women experiencing severe symptoms that are unresponsive to over-the-counter products. This channel is characterized by a higher level of patient education and engagement, as healthcare professionals discuss treatment options and monitor progress. As healthcare providers continue to prioritize personalized care, the prescription-based distribution channel is expected to maintain a significant presence in the market.

Over-the-Counter:

The over-the-counter (OTC) distribution channel is increasingly popular among women seeking immediate relief from postmenopausal vaginal atrophy symptoms. Products available OTC, such as moisturizers and lubricants, do not require a prescription, making them easily accessible and convenient for consumers. The growth of the OTC market is driven by increasing awareness about menopausal issues, and many women prefer self-management of their symptoms without the need for a doctor's appointment. OTC products are often marketed more aggressively and provide a wide range of options that cater to varying preferences and needs, thereby facilitating their rapid acceptance and adoption in the market.

By Ingredient Type

Estrogen:

Estrogen is a key ingredient in many products designed to treat postmenopausal vaginal atrophy, primarily due to its effectiveness in restoring vaginal tissue health. Estrogen therapies vary in delivery forms, including creams, tablets, and vaginal rings, allowing for personalized treatment options based on individual patient preferences. By directly addressing the hormonal deficiencies that contribute to vaginal atrophy, estrogen effectively alleviates symptoms such as dryness and discomfort. The hormonal approach has been widely endorsed by healthcare providers, contributing to the substantial market share held by estrogen-containing treatments. As ongoing research continues to highlight the benefits and safety of localized estrogen therapies, their popularity is likely to persist in the coming years.

Hyaluronic Acid:

Hyaluronic acid has emerged as a significant ingredient in non-hormonal treatments for postmenopausal vaginal atrophy, gaining recognition for its ability to retain moisture and improve tissue hydration. Products containing hyaluronic acid provide an alternative for women who are hesitant to use hormone-based therapies, as they are perceived to have a safer profile. This ingredient works by binding water to the vaginal tissues, enhancing lubrication and elasticity. As awareness of non-hormonal options expands, the demand for products featuring hyaluronic acid is expected to increase, supporting the growth of this ingredient type in the market. The simplicity and effectiveness of hyaluronic acid-based solutions also resonate well with women seeking straightforward relief from dryness and discomfort.

Dehydroepiandrosterone:

Dehydroepiandrosterone (DHEA) has gained prominence as an ingredient used in the treatment of postmenopausal vaginal atrophy due to its dual action as a precursor to both estrogen and testosterone. The conversion of DHEA to these hormones within the vaginal tissues supports restoration of function and alleviation of symptoms. Products containing DHEA are often favored by women who prefer a more natural approach to hormone therapy. Clinical studies have shown promising results in terms of symptom relief and safety, thus enhancing the acceptance of DHEA-based treatments in the market. As women continue to seek effective alternatives to traditional hormone therapies, DHEA is expected to carve out a significant share of the ingredient-based segment.

Ospemifene:

Ospemifene is a selective estrogen receptor modulator (SERM) that has been introduced as a treatment option for postmenopausal vaginal atrophy, offering a unique mechanism of action. Unlike traditional estrogen therapies, ospemifene acts selectively on estrogen receptors in the vaginal tissues, promoting their health without affecting other tissues in the body. This targeted approach makes ospemifene an appealing option for women who are either contraindicated for estrogen therapy or prefer an alternative treatment. The effectiveness of ospemifene in improving vaginal health and relieving symptoms has garnered attention among healthcare professionals, leading to its growing acceptance in the market. As research continues to support its safety and efficacy, ospemifene is anticipated to gain traction among women with postmenopausal vaginal atrophy.

Prasterone:

Prasterone, another non-hormonal ingredient making strides in the postmenopausal vaginal atrophy drugs market, is a synthetic form of DHEA that is converted to estrogen and testosterone in the vaginal tissues. This unique dual action helps restore vaginal health by enhancing lubrication and elasticity. The introduction of prasterone has been met with enthusiasm, particularly among women looking for alternatives to traditional hormone treatments. Clinical trials have demonstrated prasterone's effectiveness in relieving symptoms of vaginal atrophy, leading to its approval by regulatory authorities. As awareness grows regarding the benefits of prasterone, its market presence is expected to expand, catering to women seeking comprehensive management of their vaginal health post-menopause.

By Region

The North American region dominates the postmenopausal vaginal atrophy drugs market, accounting for approximately 45% of the total market share in 2023. Several factors contribute to this leading position, including a high prevalence of menopausal symptoms, advanced healthcare infrastructure, and strong research and development activities. Additionally, the increasing awareness and acceptance of menopausal health among women in North America have led to a growing demand for effective treatment options. The market in this region is projected to grow at a CAGR of 6.8% from 2025 to 2035 as pharmaceutical companies continue to innovate and broaden their product offerings to meet consumer needs.

In Europe, the postmenopausal vaginal atrophy drugs market is expected to witness significant growth, driven by the increasing aging population and a rising focus on women's health issues. The European market is projected to account for approximately 30% of the global market share. As healthcare policies evolve to prioritize women's health, the availability of a diverse range of treatment options is anticipated to increase, fostering greater access for women suffering from related symptoms. The market in Europe is estimated to grow at a CAGR of 5.5%, bolstered by heightened awareness campaigns and initiatives focused on destigmatizing menopausal health discussions.

Opportunities

There are numerous opportunities for growth within the postmenopausal vaginal atrophy drugs market, particularly in emerging economies where awareness of menopausal health issues is on the rise. As healthcare systems in countries across Asia Pacific and Latin America continue to develop, there is a growing recognition of the importance of addressing women’s health concerns. This trend presents a lucrative opportunity for pharmaceutical companies to expand their product offerings and distribution channels in these regions. By tailoring marketing strategies to meet the specific cultural and health needs of women in these markets, companies can effectively tap into a new customer base and enhance their market share. Furthermore, partnerships with local healthcare providers and organizations can help facilitate education and outreach efforts, addressing the stigma often associated with discussing menopausal health.

Another promising opportunity lies in the development of innovative drug delivery systems for postmenopausal vaginal atrophy treatments. Advances in technology have opened doors to new formulations and delivery methods that enhance the efficacy and safety of existing products. For instance, long-acting formulations, such as vaginal rings or implants, can provide sustained relief from symptoms, improving patient adherence and satisfaction. Additionally, the rise of telemedicine offers a platform for women to access healthcare consultations and treatment options conveniently, further expanding market opportunities. By leveraging digital health trends, pharmaceutical companies can position themselves at the forefront of innovation in the treatment of postmenopausal vaginal atrophy, ultimately benefiting both patients and their bottom lines.

Threats

While the postmenopausal vaginal atrophy drugs market presents numerous opportunities, it also faces several threats that could hinder growth. One of the primary concerns is the growing competition from alternative therapies, such as lifestyle modifications, dietary supplements, and herbal remedies. As women become more informed about their treatment options, there is potential for a shift away from pharmaceutical interventions towards these alternatives. This trend may pose a challenge for traditional drug manufacturers, as consumers seek products that align with their preferences for natural and holistic approaches to managing menopause-related symptoms. The growing popularity of these non-pharmaceutical solutions could ultimately impact the market share of established drug companies.

Another significant threat to the postmenopausal vaginal atrophy drugs market is the regulatory landscape surrounding hormone therapies. Increased scrutiny and evolving guidelines regarding the safety and efficacy of hormone-based treatments may deter some women from seeking traditional therapies. Additionally, negative media coverage and public perception regarding the risks associated with hormone replacement therapy can further create hesitancy among consumers. Companies may need to invest heavily in clinical trials and marketing to address these concerns and reassure both healthcare providers and patients about the safety of their products. Navigating these challenges will be crucial for maintaining a competitive edge in this rapidly evolving market.

Competitor Outlook

• AbbVie, Inc.
• Amgen, Inc.
• TheraTears
• HRA Pharma
• Merck & Co., Inc.
• Pfizer Inc.
• Teva Pharmaceuticals
• Endo Pharmaceuticals Inc.
• Watson Pharmaceuticals
• Novartis AG
• Valeant Pharmaceuticals International, Inc.
• Procter & Gamble Co.
• Bayer AG
• Galderma S.A.
• Johnson & Johnson

The competitive landscape of the postmenopausal vaginal atrophy drugs market is diverse, featuring several well-established players alongside emerging companies focused on innovation. Major pharmaceutical companies such as AbbVie, Merck, and Pfizer have a strong presence in the market, leveraging their extensive research and development capabilities to introduce novel therapies. Their ability to invest in clinical trials and engage with healthcare providers positions them favorably as leaders in the industry. Additionally, these companies benefit from established distribution networks and brand recognition, giving them a competitive advantage in reaching a wide consumer base.

Emerging players are also making strides in the postmenopausal vaginal atrophy drugs market. Companies like HRA Pharma and Theratears are focusing on developing non-hormonal alternatives and innovative delivery systems that cater to the growing demand for safe and effective treatment options. Their commitment to addressing unmet needs in women's health allows them to carve out niche markets and attract consumers who may be hesitant to use traditional hormone therapies. This dynamic competition fosters a continuous cycle of innovation, ensuring that patients have access to a variety of therapeutic options.

Another aspect driving competition in the postmenopausal vaginal atrophy drugs market is the emphasis on patient education and engagement. Companies are increasingly recognizing the importance of educating women about their health needs and available treatment options. By providing resources around menopausal health—such as webinars, informational websites, and consultations—pharmaceutical companies can build trust and establish relationships with consumers. As women become more informed and empowered regarding their health decisions, companies that prioritize patient engagement will likely benefit from increased loyalty and market share.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Bayer AG
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 HRA Pharma
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 TheraTears
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Amgen, Inc.
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Novartis AG
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Pfizer Inc.
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 AbbVie, Inc.
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Galderma S.A.
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Johnson & Johnson
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Merck & Co., Inc.
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Procter & Gamble Co.
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Teva Pharmaceuticals
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Watson Pharmaceuticals
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Endo Pharmaceuticals Inc.
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Valeant Pharmaceuticals International, Inc.
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Postmenopausal Vaginal Atrophy Drugs Market, By Application
    • 6.1.1 Hospital Pharmacies
    • 6.1.2 Retail Pharmacies
    • 6.1.3 Online Pharmacies
    • 6.1.4 Drug Stores
  • 6.2 Postmenopausal Vaginal Atrophy Drugs Market, By Product Type
    • 6.2.1 Estrogen Creams
    • 6.2.2 Vaginal Moisturizers
    • 6.2.3 Vaginal Lubricants
    • 6.2.4 Hormone Replacement Therapy
    • 6.2.5 Non-Hormonal Therapies
  • 6.3 Postmenopausal Vaginal Atrophy Drugs Market, By Ingredient Type
    • 6.3.1 Estrogen
    • 6.3.2 Hyaluronic Acid
    • 6.3.3 Dehydroepiandrosterone
    • 6.3.4 Ospemifene
    • 6.3.5 Prasterone
  • 6.4 Postmenopausal Vaginal Atrophy Drugs Market, By Distribution Channel
    • 6.4.1 Prescription-based
    • 6.4.2 Over-the-Counter

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Middle East & Africa - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 Middle East
      • 10.5.1.2 Africa
  • 10.6 Postmenopausal Vaginal Atrophy Drugs Market by Region

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Postmenopausal Vaginal Atrophy Drugs market is categorized based on

By Product Type

• Estrogen Creams
• Vaginal Moisturizers
• Vaginal Lubricants
• Hormone Replacement Therapy
• Non-Hormonal Therapies

By Application

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Drug Stores

By Distribution Channel

• Prescription-based
• Over-the-Counter

By Ingredient Type

• Estrogen
• Hyaluronic Acid
• Dehydroepiandrosterone
• Ospemifene
• Prasterone

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• AbbVie, Inc.
• Amgen, Inc.
• TheraTears
• HRA Pharma
• Merck & Co., Inc.
• Pfizer Inc.
• Teva Pharmaceuticals
• Endo Pharmaceuticals Inc.
• Watson Pharmaceuticals
• Novartis AG
• Valeant Pharmaceuticals International, Inc.
• Procter & Gamble Co.
• Bayer AG
• Galderma S.A.
• Johnson & Johnson